Swedish Senzime has entered into an agreement to acquire Acacia Designs BV, an international development company within anesthesia monitoring.
The acquisition will be financed by 16,076,730 newly issued shares in Senzime through a non-cash issue. After the acquisition, Acacia’s shareholders will own 50 percent of the shares in Senzime. In connection with the acquisition, a rights offering to existing shareholders will be made, amounting to 15.2 million SEK before transaction expenses. The rights offering is fully guaranteed through subscription commitments and guarantees.
Acacia is a clinical innovation company developing solutions to enable safer surgery. Acacia originates from research at Mayo Clinic, USA, and has developed novel, patent pending solutions for monitoring patients undergoing anesthesia to determine when it is safe to wake up the patient and allow spontaneous breathing following surgery. The merger of Senzime’s and Acacia’s businesses creates a company with a broad and unique offering of systems and products that continuously monitor biological and physiological processes in patients during and after surgery. Through this acquisition, Senzime obtains a significantly increased market potential.
“The acquisition of Acacia is part of our strategy to build a global leader in the field of perioperative patient monitoring. We add an entirely new product and an internationally established network to Senzime. The newSenzime will offer a broader and more complete range of products for the healthcare market,” said Lena Söderström, CEO of Senzime.
After the acquisition all operations will be conducted under the nameSenzime AB (publ).
